LIMBERGER, Tanja, Michaela SCHLEDERER, Karolína TRACHTOVÁ, Ines Garces de los Fayos ALONSO, Jiaye YANG, Sandra HOEGLER, Christina STERNBERG, Vojtěch BYSTRÝ, Jan OPPELT, Boris TICHÝ, Margit SCHMEIDL, Petra KODAJOVA, Anton JAEGER, Heidi A NEUBAUER, Monika OBERHUBER, Belinda S SCHMALZBAUER, Šárka POSPÍŠILOVÁ, Helmut DOLZNIG, Wolfgang WADSAK, Zoran CULIG, Suzanne Dawn TURNER, Gerda EGGER, Sabine LAGGER and Lukas KENNER. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis. Online. Molecular Cancer. LONDON: BioMed Central, 2022, vol. 21, No 1, p. 89-107. ISSN 1476-4598. Available from: https://dx.doi.org/10.1186/s12943-022-01542-8. [citováno 2024-04-24]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis
Authors LIMBERGER, Tanja, Michaela SCHLEDERER, Karolína TRACHTOVÁ (203 Czech Republic, belonging to the institution), Ines Garces de los Fayos ALONSO, Jiaye YANG, Sandra HOEGLER, Christina STERNBERG, Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), Jan OPPELT (203 Czech Republic, belonging to the institution), Boris TICHÝ (203 Czech Republic, belonging to the institution), Margit SCHMEIDL, Petra KODAJOVA, Anton JAEGER, Heidi A NEUBAUER, Monika OBERHUBER, Belinda S SCHMALZBAUER, Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution), Helmut DOLZNIG, Wolfgang WADSAK, Zoran CULIG, Suzanne Dawn TURNER (826 United Kingdom of Great Britain and Northern Ireland, belonging to the institution), Gerda EGGER, Sabine LAGGER and Lukas KENNER
Edition Molecular Cancer, LONDON, BioMed Central, 2022, 1476-4598.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10608 Biochemistry and molecular biology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 37.300
RIV identification code RIV/00216224:14740/22:00126463
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1186/s12943-022-01542-8
UT WoS 000776200300001
Keywords in English Prostate cancer; Senescence; Metastasis; KMT2C; MYC; p16(INK4A)
Tags CF BIOIT, CF GEN, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 19/8/2022 12:16.
Abstract
Background Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C have been detected by whole exome sequencing studies in various cancers, including malignancies of the prostate. However, the biological consequences of these alterations in prostate cancer have not yet been elucidated. Methods To investigate the functional effects of these mutations, we deleted the C-terminal catalytic core motif of Kmt2c specifically in mouse prostate epithelium. We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients. Results We show here for the first time that impaired KMT2C methyltransferase activity drives proliferation and PIN formation and, when combined with loss of the tumour suppressor PTEN, triggers loss of senescence, metastatic dissemination and dramatically reduces life expectancy. In Kmt2c-mutated tumours we show enrichment of proliferative MYC gene signatures and loss of expression of the cell cycle repressor p16(INK4A). In addition, we observe a striking reduction in disease-free survival of patients with KMT2C-mutated prostate cancer. Conclusions We identified truncating events of KMT2C as drivers of proliferation and PIN formation. Loss of PTEN and KMT2C in prostate cancer results in loss of senescence, metastatic dissemination and reduced life expectancy. Our data demonstrate the prognostic significance of KMT2C mutation status in prostate cancer patients. Inhibition of the MYC signalling axis may be a viable treatment option for patients with KMT2C truncations and therefore poor prognosis.
Links
LM2018132, research and development projectName: Národní centrum lékařské genomiky (Acronym: NCLG)
Investor: Ministry of Education, Youth and Sports of the CR, National Center for Medical Genomics
PrintDisplayed: 24/4/2024 12:03